Torrent Pharma to acquire KKR’s stake in JB Pharma for Rs. 25,689 Cr

Acquisition to be followed by merger; strengthens Torrent’s IPM market presence

FDA approves removal of REMS programs within Bristol Myers Squibb’s cell therapy labels

Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access

Biocon Biologics receives Health Canada approval for Yesafili

The approval is based on a comprehensive package of analytical, nonclinical, and clinical data

Philogen withdraws marketing authorization application for Nidlegy in EU

The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls

Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

First and only TROP2-directed therapy approved in the US for the treatment of lung cancer

Biocon concludes a Rs 4,500 crore equity fundraise through QIP

The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures

USFDA concludes inspection of NATCO’s Pharma Division, Kothur

The company received seven observations in the Form-483

USFDA inspection at the API manufacturing plant located in Mekaguda, Hyderabad

The company received one observation in the Form-483

Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease

Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression

Mezzion secures $20 million funding to advance Phase 3 clinical development of Udenafil for fontan patients